Corbus Pharmaceuticals Holdings, Inc. · NASDAQ:CRBP

Corbus Pharmaceuticals — Investor Presentation (May 2026)

58 slides from Corbus Pharmaceuticals's investor presentation, May 26, 2026

  1. Slide 1: Connecting Innovation to Purpose

    Connecting Innovation to Purpose Corporate Presentation May 26, 2026 Exhibit 99.2

  2. Slide 2: Forward-looking statements

    This presentation contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act of 1995, as amended, including those relating to the Company’s trial resul

  3. Slide 3: Two differentiated assets targeting attractive commercial opportunities

    Two differentiated assets targeting attractive commercial opportunities Therapy Disease Indication Sponsor Pre-Clinical Phase 1 Phase 2 Phase 3 Milestones NEXT-GENERATION NECTIN-4 TARGETING ADC CRB-701 Nectin-4 positive solid tumors CSPC (China) Phase 3 in cervical, Phase 2 in mUC Corbus (US + Europ

  4. Slide 4: CRB-701 Next-Generation Nectin-4 ADC targeting OPSCC and cervical cancers

    CRB-701 Next-Generation Nectin-4 ADC targeting oropharyngeal (OPSCC) and cervical cancers

  5. Slide 5: CRB-701: Reimagining the next-generation Nectin-4 ADC

    CRB-701 DAY 1 1.25 mg/kg DAY 8 1.25 mg/kg DAY 15 1.25 mg/kg DAY 22 dose holiday DAY 28 DAY 1 CRB-701 DAY 8 dose holiday DAY 15 dose holiday DAY 22 CRB-701: Reimagining the next-generation Nectin-4 ADC Source(s): Modified image from Corbus data on file; Corbus data on file; PADCEV® FDA label MMAE = M

  6. Slide 6: CRB-701-01 Study design (US and Europe)

    CRB-701-01 Study design (US and Europe) cORR, confirmed objective response rate; DLT, dose-limiting toxicity; DoR, duration of response; MMAE, monomethyl auristatin E; PFS, progression-free survival; Q3W, every 3 weeks Dose Optimization (Project Optimus): HNSCC & cervical Dose escalation Dose escala

  7. Slide 7: ASCO 2026: Key characteristics & tumor types

    Baseline Characteristic HNSCC Cervical Median age (range) 62 (24–78) 54 (32–78) Sex (M/F) 89.3% / 10.7% NA/100% ECOG PS** 0, 1, 2 47%, 52%, 1% 44%, 56%, 0% Weight in kg mean (range) 75.2 (41.3–132.8) 64.3 (39.0–99.0) Prior therapies median (range) 3 (1–9) 3 (1–7) Enrolled Tumor Types Safety Populati

  8. Slide 8: ASCO 2026: Study safety population TRAEs

    TRAE n=317 (%) Grade 3 19.2% Grade 4 0.9% Grade 5 None PERIPHERAL NEUROPATHY (broad terms*) Grade 1 and 2 7.3% Grade >3 None SKIN (most common, excluding alopecia) Pruritus 14.2% Dry skin 13.2% Rash 5.7% Grade 3 - rash 0.3% Grade ≥4 None OCULAR Overall 66.2% Grade 3 12.6% Grade 4 0.3%** DISCONTINUAT

  9. Slide 9: ASCO 2026: Safety Summary (TRAEs, N=317)

    ASCO 2026: Safety Summary (TRAEs, N=317) Source(s): ASCO April 1, 2026 data cut; *Standardized MedDRA Category Search; **general rash; TRAEs = Treatment-Related Adverse Events; Only 1 in 4 patients experienced skin AEs (excluding alopecia) Just a single Grade 3 event (1/317**) and no Grade >4 No cas

  10. Slide 10: CRB-701 in 2L+ Oropharyngeal Head and Neck Cancer (OPSCC)

    CRB-701 in 2L+ Oropharyngeal Head and Neck Cancer (OPSCC)

  11. Slide 11: What is Oropharyngeal Squamous Cell Carcinoma (OPSCC)?

    What is Oropharyngeal Squamous Cell Carcinoma (OPSCC)? Source(s): Image Corbus licensed ChatGPT account DEFINITION

  12. Slide 12: OPSCC is on the rise in the U.S. as HPV+ prevalence increases

    OPSCC is on the rise in the U.S. as prevalence of HPV+ in HNSCC is increasing: 11%  57% over last 30 years Source(s): Data generated by Greenhill: (1) Portugal et al., 1997; (2) Dahlstrom et al., 2003; (3) Chaturvedi et al., 2008; (4) Cole et al., 2012; (5) Bauml et al., 2017; (6) Wu et al., 2021;

  13. Slide 13: OPSCC growing in HNSCC: HPV+ incidence growing while HPV- decreasing

    ↑ HPV+ Pathway ↓ HPV- Pathway Two Opposing Drivers ↑ HPV+ HNSCC (younger, non-smoking patients) ↓ HPV− HNSCC (older, heavy smoker/drinker patients) OPSCC growing in HNSCC: HPV+ incidence is growing while HPV- is decreasing Source(s): Data generated by Greenhill; (1) Chaturvedi, A. K. et al., 2011; (

  14. Slide 14: Hypothesis: CRB-701 in OPSCC vs. other HNSCC?

    Hypothesis: CRB-701 in OPSCC vs. other HNSCC? Source(s): 1. Ozdogan et al 2025 2. Sander et al, 2022, 3. Swiecicki et al 2026. HPV+ tumors (80–90% of OPSCC)1 Associated with higher Nectin-4 expression2 HPV+ selectivity seen with PADCEV in 1L HNSCC3 RATIONALE

  15. Slide 15: ASCO 2026: Key characteristics in HNSCC and subsets

    Enrolled Tumor Types HNSCC All-comers ( n=75 ) OPSCC Subset ( n=41 ) Other HNSCC anatomical subsets ( n=34 ) Median age (range) 62 (24–78) 62.0 (36–77) 62 (24–78) Sex (M/F) 89.3% / 10.7% 90.2% / 9.8% 88.2% / 11.8% ECOG PS 0, 1, 2 47%, 52%, 1% 58.5%, 41.5%, 0% 32.4%, 64.7%, 2.9% Weight in kg mean (ra

  16. Slide 16: ASCO 2026: OPSCC associated with HPV positivity

    HNSCC ASCO 2026: OPSCC associated with HPV positivity in our study (as expected) Source(s): ASCO April 1, 2026 data cut BASELINE

  17. Slide 17: ASCO 2026: CRB-701 confirmed responses favor OPSCC

    2.7 mg/kg 3.6 mg/kg cORR 20.0% (4/20) 42.9% (9/21) DCR 90.0% (18/20) 85.7% (18/21) 2.7 mg/kg 3.6 mg/kg cORR 7.1% (1/14) 0.0% (0/16) DCR 57.1% (8/14) 62.5% (10/16) ASCO 2026: CRB-701 confirmed responses favor OPSCC Source(s): ASCO April 1, 2026 data cut; Patients are summarized on the treatment and d

  18. Slide 18: ASCO 2026: CRB-701 had longer durability in OPSCC

    Subject Details WEEKS ON TREATMENT 3.6 mg/kg 2.7 mg/kg ASCO 2026: CRB-701 had longer durability in OPSCC Source(s): ASCO April 1,2026 data cut; HNSCC = Head & Neck Squamous Cell Carcinoma; OPSCC = Oropharyngeal Squamous Cell Carcinoma; DoR = Duration of Response; PFS = Progression-Free Survival HNSC

  19. Slide 19: ASCO 2026: Efficacy summary at 3.6 mg/kg Q3W

    3.6 mg/kg Q3W OPSCC ( n=21 ) Non-OPSCC ( n=16 ) cORR 42.9% 0% DCR 85.7% 62.5% DoR (months) 6.3 NA PFS (months) 5.6 2.7 % responders HPV+ 89% (8 out of 9) NA ASCO 2026: Efficacy summary at 3.6 mg/kg Q3W OPSCC is indication of choice EFFICACY Source(s): ASCO April 2026 data cut; OPSCC = Oropharyngeal

  20. Slide 20: Contextualizing monotherapy CRB-701 and petosemtamab in 2L HPV+/OPSCC

    RP2D OPSCC population  Petosemtamab* (n=15)*** CRB-701** (n=21) Dosing regimen 1500mg Q2W 3.6mg/kg Q3W Efficacy (cORR) 13% (2/15) in OPSCC HPV+ only 50% (8/16) in OPSCC HPV+ only 43% (9/21) in OPSCC all types Median DoR (months) 6.2 in HNSCC 6.3 in OPSCC (ongoing) PFS (months) 4.9 in HNSCC 5.6 in O

  21. Slide 21: TEMPO-1: Registrational study in 2L OPSCC summer 2026

    TEMPO-1: Expect to launch registrational study in 2L OPSCC summer 2026 ELIGIBLE POPULATION Recurrent OPSCC Prior Platinum & Anti–PD-(L)1 RANDOMIZED 3.6 mg/kg dose 1:1 CRB-701 Monotherapy N≈125 INVESTIGATOR’S CHOICE Monotherapy N≈125 ADAPTIVE FEATURE Interim Analysis → Sample Size Re-Estimation Seaml

  22. Slide 22: 1L OPSCC potential: precedent of Padcev + Keytruda

    Padcev® + Keytruda cORR All 39% (16/41) HPV+ 82% (9/11) HPV- 23% (7/30) 1L OPSCC potential: the precedent of Padcev® + Keytruda® in 1L Source(s): 1. Swiecicki et al 2026 2. Van Herpen ASCO 2025 3.Hanna et al 2026; cORR = confirmed Objective Response Rate Investigator-assessed cORR HPV+ cORR Peto + K

  23. Slide 23: Strategy and anticipated next steps

    Strategy and anticipated next steps Broad alignment reached with FDA on a 2L registrational study with 250 OPSCC patients Report 1L CRB-701 + Keytruda® data early 2027 Seek accelerated approval based on ORR and final marketing approval based on OS Begin registrational study summer 2026 with interim

  24. Slide 24: Cervical Cancer: Acute unmet need in 2L

    Cervical Cancer Acute unmet need in 2L in poorly addressed market

  25. Slide 25: Cervical Cancer: Commercial Opportunity for CRB-701

    Cervical Cancer: Commercial Opportunity for CRB-701 Source(s): 1. https://www.cancer.org/cancer/types/cervical-cancer/about/key-statistics.html , 2. Study reveals why cervical cancer screening rates are declining, which populations are most affected - UTHealth Houston School of Public Health , 3. HP

  26. Slide 26: Few options for 2L cervical cancer

    FULL APPROVAL Few options for 2L cervical cancer Source(s): Vergote et al 2024 1L 2L Tisotumab vedotin Single-Agent Chemo Carbo + Paclitaxel +/- Beva +/- Pembrolizumab ACCELERATED APPROVAL 2021 2024 CERVICAL CANCER

  27. Slide 27: Tivdak demonstrates a commercial potential that could be further improved

    Efficacy**** ORR 17.8% PFS 4.2 months OS 11.5 months Adverse event profile**** Ocular (Black Box) 55% (all grades) Peripheral neuropathy 39% (all grades) Bleeding 51% (all grades) Rash 25% (all grades) USA numbers Value R/M patients receiving 2L treatment 38%* Annual price (WAC) $466,208** Annualize

  28. Slide 28: ASCO 2026: Key characteristics & tumor types (cervical)

    Enrolled Tumor Types Safety Population Efficacy Evaluable Population Cervical 72 70 Baseline Characteristic Cervical Median age (range) 54 (32, 78) Sex (M/F) NA/100% ECOG PS 0, 1, 2 44.4%, 55.6%, 0% Weight in kg mean (range) 64.3 (39.0–99.0) Prior therapies median (range) 3 (1–7) ASCO 2026: Key char

  29. Slide 29: CRB-701 ASCO 2026: Waterfall plot (N=70)

    CRB-701 ASCO 2026 : Waterfall plot (N=70) Source(s): ASCO April 2026 data cut; Patients are summarized on the treatment and dose level assigned at enrollment/randomization. Best Overall Response is displayed at the end of each bar. cCR = confirmed Complete response; cORR = confirmed Objective Respon

  30. Slide 30: CRB-701 ASCO 2026: Swimmer plots (N=70)

    Subject Details WEEKS ON TREATMENT 3.6 mg/kg 2.7 mg/kg CRB-701 ASCO 2026: Swimmer plots (N=70) Source(s): ASCO April 1, 2026 data cut; DoR = Duration of Response; PFS = Progression-Free Survival Months 2.7 mg/kg ( n=38 ) 3.6 mg/kg ( n=32 ) DoR 6.8 8.0 PFS 2.8 4.3 CERVICAL Complete Response Partial R

  31. Slide 31: CRB-701 potential to differentiate from current standard of care in 2L

    CRB-701* ( n=32 ) Tivdak® ( n=253**) IC Chemo 2L+ ( n=249*** ) Mechanism Nectin-4 ADC with MMAE payload (DAR 2) Tissue factor ADC with MMAE payload (DAR 4) Anti-metabolite, cytoskeleton disruption, topoi inhibition etc. Target population 2L 2L 2L Dosing regimen 3.6 mg/kg Q3W 2 mg/kg Q3W various Effi

  32. Slide 32: Strategy and anticipated next steps

    Strategy and anticipated next steps Broad alignment reached with FDA on a registrational study in 2L cervical cancer Oral presentation at ASCO 2026 Seek accelerated approval based on ORR and full marketing approval based on OS Control arm: Physicians’ choice standard of care (Tivdak® or chemo) NEXT

  33. Slide 33: CRB-913 Daily oral small molecule targeting chronic obesity management

    CRB-913 Daily oral small molecule targeting chronic obesity management Data from Phase 1a SAD/MAD study

  34. Slide 34: What are the emerging unmet needs in the obesity landscape?

    % Patients on incretin Tx (Real world data) What are the emerging unmet needs in the obesity landscape? Source(s): *Cartwright et al 2025, **AP Nov 2024 GLP-1 discontinuation @ 1 year for obesity patients* 64%

  35. Slide 35: CRB-913's opportunity to reshape the obesity treatment paradigm

    Alternatives to GLP-1 for resistant/intolerant/ partial-responders Lifelong weight maintenance using daily pill post weight loss Avoiding sarcopenia CRB-913's opportunity to reshape the obesity treatment paradigm

  36. Slide 36: CB1 inverse agonism is a new non-incretin MOA

    MOA Company Function Monotherapy weight loss? CB1 inverse agonism Corbus, Novo Appetite suppression, weight loss & muscle sparing Yes Pan-agonist bitter taste receptor Aardvark Appetite suppression No INHBE siRNA Wave, Arrowhead Fat reduction + muscle buildup No CB1 inverse agonism is a new non-incr

  37. Slide 37: CB1 is a well-understood receptor in metabolism

    CB1 is a well-understood receptor in metabolism Source(s): Targeting the endocannabinoid system in diabesity: Fact or fiction?, Drug Discovery Today, Deeba et al. Mar 2021. PAPERS 9K in PubMed on CB1 and metabolism

  38. Slide 38: CRB-913 is designed to be a highly peripherally restricted inverse agonist

    CRB-913 is designed to be a highly peripherally restricted inverse agonist Source(s): *Corbus murine data; **Corbus PK modeling CRB-913 1/50th Brain:plasma ratio CRB-913 vs. Rimonabant* 1/15th Brain level CRB-913 vs. Monlunabant* Rimonabant Otenabant Ibipinabant Taranabant Monlunabant 30% Increase i

  39. Slide 39: How does peripheral CB1 inverse agonism affect appetite?

    How does peripheral CB1 inverse agonism affect appetite? Appetite Fat Oxidation Recent paper sheds light on potential MOA:

  40. Slide 40: CRB-913 SAD/MAD study design

    25 mg 75 mg 150 mg 300 mg CRB-913 SAD/MAD study (Phase 1 unit in US, total n=112) Source(s): Corbus SAD/MAD data 150 mg Participants with obesity # PER COHORT Placebo 2 CRB-913 6 150 mg Fed Single Ascending Dose (SAD) (n=64) CONTEXT Rimonabant efficacious dose: 20 mg QD / Monlunabant efficacious dos

  41. Slide 41: Emerging weight loss observed with CRB-913 in participants with obesity

    Emerging weight loss observed with CRB-913 in participants with obesity (150 mg MAD cohort) Source(s): December 2025 MAD Data Note: Baseline is defined as the last available measurement taken prior to the first dose of study drug. Percent change in body weight is defined as body weight at Day 14 min

  42. Slide 42: Weight loss observed with CRB-913 starts early and deepens

    Weight loss observed with CRB-913 starts early and deepens Source(s): December 2025 MAD Data Baseline is defined as the last available measurement taken prior to the first dose of study drug. Percent change in body weight is defined as body weight at the given day minus body weight at baseline divid

  43. Slide 43: Signals of weight loss in all-comer participants in MAD cohorts

    Placebo-adjusted weight loss 0% 2.0% 1.5% BMI range 23.5 to 31.4 22.3 to 31.8 24.4 to 31.3 Signals of weight loss in all-comer participants in MAD cohorts at lower doses Source(s): December 2025 MAD Data Baseline is defined as the last available measurement taken prior to the first dose of study dru

  44. Slide 44: CRB-913 vs. orforglipron MAD: Deeper and faster weight loss?

    Placebo-adjusted weight loss cross-trial comparison for MAD studies 2mg 6mg 16mg 24mg 150 mg CRB-913 0 -1 -2 -3 -4 8 15 22 29 Emerging data CRB-913 vs. orforglipron MAD: Deeper and faster weight loss? Source(s): All comparator data points are approximated and based on extracted figures reported from

  45. Slide 45: CRB-913 vs. Orforglipron MAD data: Differentiated emerging safety

    Adverse Event CRB-913* Orforglipron** GI TOLERABILITY Nausea None 12%–22% Constipation None 11%–23% Vomiting None 0%–18% NEUROPSYCH CSSRS Negative Negative PHQ-9 Negative Negative GAD-7 Negative Negative CRB-913 vs. Orforglipron MAD data: Differentiated emerging safety Source(s): *Corbus December 20

  46. Slide 46: Contextualizing weight loss in 2 weeks across oral MAD obesity data sets

    Drug Company Placebo Adjusted WL (%) Type CRB-913 (150 mg) -2.9% Small molecule Orforglipron (2 mg) -1.4% small molecule Aleniglipron (5 mg) -1.3% small molecule Elecoglipron (50 mg) 0% small molecule Semaglutide (40 mg) -0.7% oral peptide VK2735 (30 mg) -1.8% oral peptide Contextualizing weight los

  47. Slide 47: Potential clinical usage (1 of 3)

    Potential clinical usage and supportive clinical or pre-clinical data (1 of 3) INSENSITIVE PATIENTS Only hope is non-incretin MOA INTOLERANT PATIENTS CRB-913 has markedly mild GI tox HIGH RISK PATIENTS (sarcopenia) CB1 inverse agonism not associated with sarcopenia 1 CRB-913 monotherapy therapy for

  48. Slide 48: Potential clinical usage (2 of 3)

    Potential clinical usage and supportive clinical or pre-clinical data (2 of 3) Source(s): Morningstar et al 2023 2 Combination with oral incretin agonists  potentially enhances efficacy OR improve tolerability

  49. Slide 49: Potential clinical usage (3 of 3)

    Potential clinical usage and supportive clinical or pre-clinical data (3 of 3) Source(s): Morningstar et al 2024 3 “Induction/maintenance” model: Goal to potentially maintain weight loss post incretin analog therapy Vehicle PO QD Semaglutide Day 1–41 Semaglutide Day 1–21; Vehicle Day 22–41 Semagluti

  50. Slide 50: Weight loss from CRB-913 driven by further fat loss following semaglutide

    At day 41 ( end of study period ) SEMA  SEMA SEMA  CRB-913 DIFFERENCE Weight loss (%) -13.6 -17.1 ↑ 25% Fat change from baseline -3.65% -8.65% ↑ x2.3 Weight loss from CRB-913 driven by further fat loss following semaglutide in DIO mouse model Source(s): Morningstar et al 2024 ** SEMA  SEMA SEMA 

  51. Slide 51: What could the addressable market opportunity look like for CRB-913?

    What could the addressable market opportunity look like for CRB-913? Source(s): *Cartwright et al 2025; **AP Nov 2024 % Patients on incretin Tx (Real world data) Induction by incretin analogs  maintenance by CRB-913 AND / OR Combo-therapy for additional weight loss Orthogonal MOA CRB-913 in line wi

  52. Slide 52: Initiated: Phase 1b study (CANYON-1)

    Initiated: Phase 1b study COMPLETION SUMMER 2026 CRB-913 phase 1b ( CANYON-1 ) Monlunabant phase 2a Subjects with obesity 240 240 Location USA Canada Cohorts (all QD) Placebo, 20, 40 and 60 mg Placebo, 10, 20 and 50 mg Titration Yes No Exclude PHQ-9 > 4 at baseline Yes No Matching Placebo QD 12-Week

  53. Slide 53: What did we learn from the CRB-913 SAD/MAD data?

    What did we learn from the CRB-913 SAD/MAD data? High peripheral restriction  favorable safety + tolerability CRB-913 elicits weight loss that starts early and deepens Weight loss is not driven by GI AEs Weight loss is associated with restriction to the periphery

  54. Slide 54: Leadership; Upcoming Catalysts

    Leadership Upcoming Catalysts

  55. Slide 55: Management Team

    Management Team Yuval Cohen, PhD Chief Executive Officer, Director Corbus co-founder and Chief Executive Officer since 2014. Previously the President and co-founder of Celsus Therapeutics from 2005. Sean Moran, CPA, MBA Chief Financial Officer Corbus co-founder and Chief Financial Officer since 2014.

  56. Slide 56: Board of Directors

    Board of Directors Winston Kung, MBA Director More than 20 years of senior financial, business development and investment banking experience; currently CFO of ArriVent. (NASDAQ: AVBP) Yuval Cohen, PhD Chief Executive Officer, Director Corbus co-founder and Chief Executive Officer since 2014. Previousl

  57. Slide 57: Upcoming anticipated corporate milestones

    Upcoming anticipated corporate milestones FDA update - registrational study protocol Phase 1/2 monotherapy data CRB-701 + Keytruda® 1L OPSCC data April 2026 Mid-2026 Early 2027 CRB-701 Complete Phase 1 SAD/MAD Start Phase 1b study Complete Phase 1b dose ranging study Q4 2025 Q4 2025 Summer 2026 CRB-

  58. Slide 58: Slide 58

Corbus Pharmaceuticals Holdings — Investor Presentation (May 2026) on 6ix